BIO
The table below shows Bio-Rad Laboratories, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|
| Revenue | $592.10M | $653.00M | $651.60M | $585.40M | $667.50M | $649.70M |
| Cost of revenue | $282.70M | $309.60M | $306.30M | $279.40M | - | $293.80M |
| Gross profit | $309.40M | $343.40M | $345.30M | $306.00M | $342.00M | $355.90M |
| R&D | $62.90M | $71.30M | $60.50M | $73.50M | - | $91.00M |
Bio-Rad Laboratories, Inc. reported annual revenue of $2.58B for fiscal year 2025. That is up 0.7% from $2.57B in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $2.07B (FY 2016) to $2.58B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A | $212.40M | $206.80M | $207.70M | $208.80M | - | $200.40M |
| Operating income | $34.10M | $65.30M | $77.10M | $23.70M | - | $64.50M |
| Income tax | -$162.70M | -$89.20M | $96.20M | $19.40M | - | $208.40M |
| Net income | -$527.10M | -$341.90M | $317.80M | $64.00M | -$715.80M | $653.20M |
| EPS (diluted) | -$19.55 | -$12.70 | $11.67 | $2.29 | -$25.57 | $23.34 |